Leon Aarons

Abstracts

ISoP Lecture 2014: What have models ever done for you?

Leon Aarons
The University of Manchester
January 24, 2014January 24, 2014

In this talk I will look critically at the role of modelling within drug research. The theme is basically that many people model for modelling sake without thinking what they are doing. Personally I think this gives modelling a bad name and could be dangerous (but probably not). I will go through a number of […]

Abstracts

Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children

L. Aarons(1), B. Sadler(2), M. Pitsiu(3), J. Sj
(1)School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK; (2)Icon Development Solutions, Ellicott City, MD, USA; (3)Icon Development Solutions, Manchester UK; (4)Clinical Pharmacology & DMPK, AstraZeneca R&D S
January 10, 2012

Objectives: The aim of the present study was to characterize ropivacaine and PPX pharmacokinetics and factors affecting them in paediatric anaesthesia. Methods: Population pharmacokinetics of ropivacaine and its active metabolite PPX were estimated following single and continuous ropivacaine blocks in 192 patients aged 0-12 years from six pooled published studies. Unbound and total ropivacaine and […]

Abstracts

Identifiability of random effects parameters in mixed effects models

Leon Aarons
The University of Manchester
January 5, 2010January 9, 2013

Identifiability of random effects parameters in mixed effects models In-Sun Nam Knutsson and Leon Aarons School of Pharmacy and Pharmaceutical Sciences The University of Manchester Manchester, U.K. Structural identifiability deals with the ability to uniquely identify parameters given perfect data. A model is said to be globally identifiable if only one set of parameters uniquely […]